Skip to main content

23 publications

Name Date Type Actions

2008 annual earnings

The Vétoquinol Board of Directors, meeting on March 20, 2009, reviewed the group’s business and approved the group’s 2008 financial statements.

31/03/2009 Public releases

2008 revenue: €234.4 M

Revenue grew in 2008, despite poor economic conditions in the second half and
an unfavourable comparison effect

22/01/2009 Public releases

2009 Revenue improvement in trends in the first quarter

Vétoquinol’s revenue for the first quarter of 2009 reached €57.1 M, an increase of 4.4% over the first quarter of 2008.

09/04/2009 Public releases

2010 annual earnings

Lure (France), April 4, 2011 – Vétoquinol’s Board of Directors, meeting on March 18, 2011, has reviewed the Group’s business and approved its 2010 financial statements.

04/04/2011 Public releases

2010 Revenues grow 11.8%, driven by organic growth

The Vétoquinol Group reports sustained sales growth driven by its “hybrid” business model, supported by a sound level of organic growth.

25/01/2011 Public releases

European launch of new Nsaid Cimalgex®

Lure (France), June 14, 2011 – Vetoquinol announces the European launch of CIMALGEX®, a new treatment for pain and inflammation in dogs.

14/06/2011 Public releases

Forcyl®: european launch of new drug

Lure (France), September 29, 2011 – Vétoquinol announces the European launch of Forcyl®, a new drug based on 16% concentrated marbofloxacin allowing the treatment of cattle respiratory infections with a single injection.

29/09/2011 Public releases

Growth in Revenues in the first half of 2009

Vétoquinol’s revenues in the first half of 2009 totalled EUR 119.9 million, an increase of 2.7% compared to the first half of the preceding year.

16/07/2009 Public releases

Information relative à un engagement du Conseil d’Administration pris au bénéfice du Directeur Général Délégué Groupe (french)

Lors de sa réunion du 13 mars 2009, le Conseil d’Administration a pris l’engagement, dans le cadre de la loi du 21 août 2007, de verser une indemnité à Monsieur Dominique HENRYON, Directeur Général Délégué Groupe, en cas de révocation de ce dernier pour tout autre motif qu’une faute grave. Cette décision se substitue à celle du 1er décembre 1998.

30/03/2009 Public releases

International expansion and new product launches

Lure (France), July 19, 2011 – Vétoquinol Group sales rose to €139.7 million in the first six months of 2011.

19/07/2011 Public releases